Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction

CONCLUSIONS: Empagliflozin is effective in reducing LV volumes and hospitalisation rate in patients with type 2 diabetes and prediabetes and HFrEF. Therefore, treatment with empagliflozin for six months was associated with a significant reduction in adverse cardiovascular outcomes in these patients.PMID:38511517 | DOI:10.1080/00015385.2023.2240130

Source: Acta Cardiologica - March 21, 2024 Category: Cardiology Authors: Mohammad Reza Afshani Ekhlas Torfi Nehzat Akiash Alireza Jahanshahi Asghar Mohamadi Omid Sherafat Source Type: research